Dalbavancin for treating prosthetic joint infections caused by Gram-positive bacteria: A proposal for a low dose strategy. A retrospective cohort study

ABSTRACT

Background. Gram-positive bacteria are the leading cause of prosthetic joint infection (PJI). Dalbavancin is a lipoglycopeptide with remarkable pharmacokinetic properties and high bactericidal activity against most Gram-positive bacteria. Although clear evidence regarding its effectiveness in bone and joint infections lacks, recent studies suggest a promising role of dalbavancin in PJI.

Methods. From June 1st 2016 to May 1st 2018, all patients diagnosed of PJI and treated with DAL alone or in combination with other drugs were retrospectively evaluated. Dalbavancin susceptibility of every isolate was studied following CLSI criteria. The primary objective was to assess the clinical efficacy and tolerability of the drug in patients with PJI. A cost-analysis was performed following the DALBUSE study methodology.

Results. Sixteen patients were treated with dalbavancin, eight with total hip arthroplasty infection (THAI) and eight with total knee arthroplasty infection (TKAI). Staphylococcus spp. and Enterococcus spp. were the microorganisms involved. No major side effects were detected. Infection resolved in 12 patients. In 2 patients the treatment failed, and another patient died due to unrelated causes. One patient is currently being treated for hematogenous-spread knee infection secondary to prosthetic aortic arch endocarditis. After discontinuation of dalbavancin, and excluding patients who died or with clinical failure, the median follow up of the cohort was 503 days (interquartile range IQR, 434.5 to 567 days). We calculate that US$ 264,769 were saved.

Conclusion. This study suggests that dalbavancin treatment for PJI caused by Gram-positive bacteria is a safe and effective option that reduces hospital stay and costs. Future reports are needed to confirm these findings.

Keywords: Prosthetic joint infection, dalbavancin, safety, efficacy

RESUMEN

Introducción. Las bacterias grampositivas son la principal causa de infección periprotésica (IPP). Dalbavancina es un lipoglicopéptido con interesantes propiedades farmacocinéticas y una importante actividad bactericida frente a la mayoría de gram positivos. Aunque aún necesitamos mayor evidencia en relación con su uso en infección osteoarticular, estudios recientes sugieren un papel importante de dalbavancina en la IPP.

Métodos. Desde el 1 de Junio de 2016 al 1 de Mayo de 2018, todos los pacientes diagnosticados con IPP y tratados con dalbavancina sola o en combinación con otros fármacos fueron evaluados de forma retrospectiva. La sensibilidad a dalbavancina de los aislamientos fue evaluada según las recomendaciones de CLSI. El objetivo primario fue determinar la eficacia y tolerabilidad del fármaco en pacientes con IPP. Se realizó un análisis de coste siguiendo la metodología descrita en el estudio DALBUSE.

Resultados. Dieciséis pacientes fueron tratados con dalbavancina, ocho con infección de prótesis total de cadera y ocho con infección de prótesis total de rodilla. Staphylococcus spp. y Enterococcus spp. fueron los microorganismos implicados. No hubo efectos adversos relevantes. La infección se resolvió en 12 pacientes. En dos pacientes el tratamiento falló, y otro paciente falleció por causas no relacionadas. Un
Dalbavancin for treating prosthetic joint infections caused by Gram-positive bacteria: A proposal for a low dose strategy. A retrospective cohort study

L. Buzón Martín, et al.

Rev Esp Quimioter 2019;32(6): 532-538

was consent obtained from all patients included in the study. Informed unavailability of other orally-administered choices. Informed failure of other antibiotics, their toxicity, interactions and/or choosing DAL in each particular case, generally, because of DAL was withdrawn to consider PJI to be cured. year of follow-up without clinical relapse was required after Prosthetic Joint Infections diagnostic criteria [7]. At least one diagnosed following the International Consensus Meeting on objective was to assess the clinical efficacy and tolerability treated with DAL were retrospectively reviewed. The primary was from endocarditis protésica aórtica. Tras la discontinuación of dalbavancina, y exceptuando los pacientes fallecidos y/o con fallo terapéutico, el seguimiento medio fue de 503 días (rango intercuartílico 434.5-567 días). Se estimó un ahorro de 264.769 dólares USA.

Conclusiones. Este estudio sugiere que dalbavancina para del tratamiento de IPP causada por microorganismos gram positivos es segura y una opción eficaz que reduce la estancia hospitalaria y los costes. Se precisan más comunicaciones para confirmar estos datos.

Palabras clave: infección periprotésica, dalbavancina, seguridad, eficacia

INTRODUCTION

Total joint arthroplasty is a widely used treatment modality for knee (TKA) and hip (THA) osteoarthritis. In 2010, more than 310,800 THA and 639,400 TKA were performed in the United States. Prosthetic joint infection (PJI) is a major complication, occurring in 1–2% of primary joint arthroplasties and up to 10% of revision surgeries [1, 2].

Dalbavancin (DAL) is a lypoglycopeptide structurally related to teicoplanin, approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIIs) with bactericidal activity against most Gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA) [3]. Recent studies show that DAL is an effective option to be considered in patients with bacteriemia, endocarditis and ostearticular infections [4].

Given the few reports on DAL administration for PJI, its dosage scheme is not standardized. However, its unique capacity to achieve high and stable concentrations in bone and peri-articular tissues [5] allows prolonged and cost-effective [6] treatment of PJI caused by Gram-positive microorganisms.

MATERIAL AND METHODS

From June 1st 2016 to May 1st 2018, all patients older than 18 years of age, diagnosed of PJI in our institution and treated with DAL were retrospectively reviewed. The primary objective was to assess the clinical efficacy and tolerability of the drug when used in real life to treat PJI. PJI cases were diagnosed following the International Consensus Meeting on Prosthetic Joint Infections diagnostic criteria [7]. At least one year of follow-up without clinical relapse was required after DAL was withdrawn to consider PJI to be cured.

Currently, PJI is an off-label indication of DAL. Patients were appropriately informed about using DAL as an off-label medication for PJI, its potential toxicity and the reasons for choosing DAL in each particular case, generally, because of failure of other antibiotics, their toxicity, interactions and/or unavailability of other orally-administered choices. Informed consent was obtained from all patients included in the study. The study protocol was approved by the Institutional Ethics Committee (research approval reference number: 2018).

Staphylococcus spp. susceptibility to DAL and E. faecalis susceptibility to vancomycin were confirmed by the E-test method, following CLSI criteria. However, antimicrobial concentrations that confirm susceptibility of Enterococcus faecium to DAL and Enterococcus faecalis to vancomycin are not well defined according to CLSI and EUCAST guidelines [8].

RESULTS

Table 1 shows the main clinical features of the cohort. A total of 16 patients (9 males, 56%) were included in the analysis. Median age was 76 years and median age-adjusted Charlson index was 3 (IQR 3-5) (see table 2). Coagulase-negative staphyloccoci (CoNS) were the most commonly isolated microorganisms (7 cases, 43.7%), followed by MRSA and E. faecium with four cases (25%), while E. faecalis was involved in only one case (6.25%). THAi and TKAi occurred in 8 patients each. Eleven cases (68.7%) were considered chronic PJI. Seven patients (43.7%) were treated with two-stage revision arthroplasty and antibiotic-impregnated articular spacers. Two patients needed surgical debridement (patients #5 and #10, table 1) due to comorbidities; Patient five had undergone a resection arthroplasty months before and drainage of the abscess and diaphysitis was performed with no prosthesis reimplantation due to poor bone stock. Two patients (patients #7 and #16) were treated with suppressive antimicrobial treatment, but no surgery.

The reasons for choosing DAL in each patient are detailed in table 1. DAL was used as monotherapy in 11 patients (68.7%). One patient received DAL in association with oral rifampicin that was ultimately discontinued because of hepatic toxicity. Four patients received oral dicalcic fosfomycin in an outpatient basis concurrent with DAL, without showing major side effects. In most cases, rifampicin could not be used, mainly because of interactions with oral anticoagulants (3 out of 11) and immunosuppressive drugs for solid organ transplantation (patient number 13, table 1, one out of eleven).

A total of 9 patients (56%) received 1.5 g of DAL as loading dose, followed by 0.5 g at day seven, and then 0.5 g every two weeks for two months in THAi and for three months in TKAi. This treatment scheme was termed Low Dose Bi-weekly Dalba- vancin, or LDBD. Once DAL therapy ended, and after excluding patients who died or had clinical failure (table 1) were followed for a median 503 days (interquartile range IQR, 434.5 to 567 days). Side effects attributable to medication were on one case of mild skin macular rash and one case of mild transient leukopenia.

Excluding one patient, who died of an unrelated cause at three months of follow up (patient #10, table 1), currently, 12 patients (80%) show no clinical, pathological, biochemical, microbiological and/or gammagraphic signs of infection. Two different strains of previously identified microorganisms were found in different tissue samples obtained from two patients.
Table 1  Clinical characteristics of the patients treated with dalbavancin

| Patient # | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 |
|-----------|---|---|---|---|---|---|---|---|---|----|----|----|----|----|----|----|
| Age       | 66 | 80 | 75 | 69 | 77 | 87 | 77 | 69 | 70 | 92 | 78 | 85 | 71 | 83 | 71 | 75 |
| Sex       | M  | M  | M  | M  | M  | M  | F  | F  | M  | M  | F  | F  | M  | F  | F  | M  |
| Charlson  | 2  | 5  | 2  | 3  | 3  | 7  | 3  | 5  | 3  | 7  | 5  | 7  | 3  | 4  |    |    |
| Infection | Early THAi | Ch TKAi | Ch THAi | UIPC (THA) | Dyaphisitis after G | Ch THAi | UIPC (TKA) | Ch THAi | Ch THAi septic pseudoarthrosis | Ch TKAi | Ch THAi | Ch TKAi | Acute hem TKAi | Acute hem TKAi | Early TKAi | Acute hem TKAi |
| Surgery   | 2SE | 2SE | G  | 2SE | G  | G  | ZSE | ZSE | Drainage | ZSE | ZSE | Drainage | Prophylactic removal & Arthrodesis | DAIR | Prophylactic removal | 2SE | AIAS |
| Aetiology | MSSA & CoNS | MSSA & CoNS | Ef | Ef | MSSA | Ef | CoNS | Se | Ef and Se | MRSA | Se | MRSA & Se | Efa | Efa | MRSA | Efa |
| Reasons for DAL use | NOBCA | INTa | TOX | FOC | TOX | FOC | NOBCA | NOBCA | NOBCA | FOC | NOBCA | NOBCA | NOBCA | NOBCA | NOBCA | NOBCA |
| DAL dosing | 1g day 1 | 1g day 1 | 1g day 1 | 1g day 1 | 1g day 1 | 0.5 g 8w | LDBD | LDBD | LDBD | LDBD | LDBD | LDBD | LDBD | LDBD | LDBD | LDBD |
| Days of follow up since DAL stop | 498 | 777 | 647 | 592 | 540 | 542 | 422 | 447 | 467 | 94 | Clinical failure | 508 | 70 | 350 | 313 | Ongoing |
| Outcome   | C  | C  | C  | C  | C  | C  | C  | C  | C  | Died | Fa | C  | F  | C  | C  | Ongoing |

*CoNS obtained from surgical samples showed clinical susceptibility after clinical failure. Ef: *Enterococcus faecium*, Efa: *Enterococcus faecalis*. IE: infective endocarditis, 2SE: 2 stage Exchange, AIAS: antibiotic impregnated articular spacer, C: Cured, Ch: Chronic, CF: Clinical failure, CoNS: coagulase-negative staphylococci, INT: Interactions, FOC: Failure with other choices, G: Girdlestone, LDBD: Low dose biweekly DAL: 1.5 g. day1, 0.5 g. day7, then biweekly, NOBCA: No oral better choice available, Se: *Staphylococcus epidermidis*, THAi: Total hip arthroplasty infection, TKAi: Total knee arthroplasty infection, TOX: Toxicities, UIPC: unsuspected intraoperative positive cultures, W: weeks
The use of DAL in such cases allows earlier hospital discharge, thus reducing the length of stay and cost.

Biedenbach et al analyzed the activity of DAL against a large collection of Gram-positive microorganisms: The minimal inhibitory concentration \( \text{MIC}_{90} \) for \( S. \text{aureus} \) was 0.06 mg/L, and 99.9% of microorganisms were inhibited at concentrations of 0.12 mg/L. The \( \text{MIC}_{90} \) was 0.06 mg/L and 0.12 mg/L for oxacillin-susceptible and oxacillin-resistant CoNS, respectively. For \( E. \text{faecalis} \) and \( E. \text{faecium} \), the \( \text{MIC}_{90} \) values were 0.06 and 0.12 mg/L, respectively. Thus, bactericidal concentrations in plasma, bone and peri-articular tissues are achievable with usual therapeutic concentrations [11]. Special attention deserves the fact that the activity of DAL against CoNS isolates with teicoplanin MIC values higher than 8 mg/L may be impaired, and teicoplanin MIC values higher than 16 mg/L almost invariably results in DAL non-susceptibility[12].

Another important issue is DAL activity against bacterial biofilms in PJI. DAL has proved in in vitro models to be a powerful inhibitor of bacterial colonies, in which structural and functional bacterial differentiation, once embedded in the extracellular matrix, promote microorganisms to be highly resistant to antibiotics whether or nor they were primarily susceptible to the drug [13].
Another relevant aspect of the antibiotic treatment in PJI is the ability of the drug to reach adequate and stable concentrations in bone and peri-articular tissues. A phase I trial evaluated the penetration of DAL in bone and articular tissues in healthy patients who received DAL up to 14 days before elective orthopedic surgery. Bone concentration of DAL measured 12 hours and 14 days post-dose were 6.3 µg/dl and 4.1 µg/dl, respectively, much higher than MIC₉₀ of target microorganisms in PJI [5]. A two-dose 1.5 g once a week regimen was proposed for the treatment of acute osteomyelitis, in a single-center open-label study comparing DAL with standard treatment. Staphylococcus spp. and Enterococcus spp. were the causative agents of 91% of cases. The outcomes reported suggest that DAL was highly effective and safe for treating acute osteomyelitis. However, patients with prosthetic implants at the site of infection were excluded in this study [14].

Recently, a Spanish multicenter real life experience with the use of DAL in different clinical settings has been published. It included 20 cases of PJI retrospectively collected in one year from 29 national institutions that presented favorable clinical outcomes [9]. Again, Staphylococcus spp. and Enterococcus spp. were the etiological agents of 90% of the PJI cases. Eighty percent of the cases exhibited a “successful clinical outcome”. However, no specific data regarding DAL dosing scheme was provided.

In our institution, DAL was firstly used for the treatment of PJI in June 2016. Most of the clinical experience previously cited was not available at that moment, and there were no standard recommendations for dosage. Throughout the following two years, 15 cases of PJI were treated with DAL. As mentioned, most of them were elderly patients with complex co-morbidities. The first six cases were treated with DAL 1.5g every week, for a variable period of time. As we gained experience, we turned to a regimen of 1.5g at day 1 and 0.5g at day 7, followed by 500 mg every two weeks for two months in THA infections and for three months in TKA infections (LDBD). This treatment scheme is supported by the fact that DAL concentration in bone and peri-articular tissues after 14 days of administration are high enough for Gram-positive microorganism inhibition [5], and patients markedly improve following the first two doses. Whether just two doses of DAL are enough for infection control remains a controversial issue. According to the study by Rappo et al., patients with PJI who underwent surgical removal of the prosthesis and debridement, in one or two stages, fared well after two doses of DAL in acute osteomyelitis. On the basis of this published experience and supported by the favorable outcome of our first cases, we decided to use the LDBD as the standard regimen in our institution.

One of the reasons for choosing DAL was the unavailability of other orally administered antibiotics for this indication (table 1). Ideally, rifampicin should be added to any therapeutic regimen for PJI after surgeries with prosthesis retention, due to its activity against Gram-positive bacterial biofilms [10]. In our case series, reasons for not using rifampicin were resistance and/or interactions that precluded its use: three patients were taking oral anticoagulants, and another three were taking drugs with major interactions, including a patient who was a kidney transplant recipient receiving immunosuppressive drugs. DAL remained effective even though rifampicin could not be used. Oral (dicalcic) fosfomycin was used in three cases caused by MRSA, E. faecalis and CoNS, presenting no major side effects. We did not use trimethoprim-sulfamethoxazole because CoNS are commonly resistant, and the presence of gross purulence favors its failure [15]. There were reasons for choosing DAL instead of linezolid: half of the patients were taking serotonin reuptake inhibitors, with the consequent risk of serotoninergic syndrome [16], and five patients showed preexisting anemia and/or chronic kidney disease [17], and another patient had a myelodysplastic syndrome.

Four of our cases deserve a special comment. In the first case (case #13), a 71 year-old woman, who had received a kidney transplant three months before, developed an acute hematogenous prosthetic knee infection originating from a subclavian venous catheter infection, that had been used for hemodialysis until transplantation surgery, which had remained placed for the treatment of mild rejection, caused by an oxacillyn-resistant CoNS that could be isolated from blood, periprosthetic effusion and the subclavian catheter tip. Debridement and retention with mobile elements exchange was performed. Three months after DAL administration had been discontinued, C reactive protein (CRP) and erythrocyte sedimentation rate (ESR) values were normal. However, six months afterwards, recurrent infection was suspected due to inflammatory signs and the presence of peri-prosthetic abscess. A two-stage revision arthroplasty was performed. All samples yielded Staphylococcus species, different from the one previously isolated, but fully susceptible to DAL. Interestingly, this patient did not receive rifampicin due to major interactions with immunosuppressive drugs. In the other three patients the prosthesis was not removed for different reasons, a clinical scenario in which treatment failure is likely. In case #7, a 77 year-old woman developed an acute TKA infection. The patient refused revision surgery and DAL monotherapy was then used: 1,500 mg were administered at day 1 and 7, then every two weeks for 6 months. After 373 days of follow up, there are no signs of clinical relapse, and ESR and CRP values are normal with knee function preserved. In case #10, a 95 year-old man with a chronic TKA PJI and surrounding soft tissues infection caused by MRSA was treated with DAL monotherapy with LDBD. Surgery was not performed because of advanced dementia. Clinical response was remarkable, with functional improvement of the affected knee and normalization of CRP after the first two doses of LDBD. After the third and fourth doses, he was changed to oral cotrimoxazole. He died two months later due to unrelated causes with no clinical signs of relapse. In case #16, a 75 year-old man was diagnosed of prosthetic aortic arch infective endocarditis (Bono-Bentall procedure) with secondary haematogenous TKA infection caused by E. faecalis (positive in blood cultures and sinovial fluid) with a confirmatory PET-CT scan. Cardiac surgery was discarded due to excessive surgical risk. After receiving intravenous ampicillin and ceftriaxone, followed by daptomycin and fosfomycin (because of...
ampicillin-associated reversible leukopenia), he was ultimately changed to 1.5 g of DAL on day 1 and 7, then 1.5 g every two weeks and then suppressive treatment with a monthly dose of 1.5 g. After the fifth monthly dose, hematocrit, CRP and ESR have returned to normal values and the patient has no symptoms or signs of clinical relapse.

DAL is effective against *Staphylococcus* spp, and clear susceptibility breakpoints are well established in both CLSI and EUCAST recommendations [7, 10]. Clinical reports and in vitro experiments show that DAL is highly bactericidal against susceptible enterococci [18] and has activity against biofilms formed by DAL-susceptible enterococci [19–20]. However, no susceptibility breakpoints have been determined yet by CLSI or EUCAST for vancomycin-resistant *E. faecalis* and *E. faecium*. Nevertheless, based on previous clinical reports and lacking potentially better and safer options, DAL was successfully used in five cases. Our experience is in line with previous reports regarding DAL efficacy for the treatment of enterococcal infections.

As previously reported, toxicity attributable to DAL administration was negligible. No major side effects were detected, apart from mild transient grade I leukopenia and a mild transient rash in one patient. DAL therapy allowed early discharge of most of the patients, with a presumably relevant impact in terms of healthcare costs. Applying the same cost analysis previously reported by Bouza et al. in the DALBUSE study, we calculated that 571 days of hospitalization were avoided, and a total of US$ 264,769 were saved.

Our study has important limitations. It reflects a single center experience and potential biases may be present. Nevertheless, the data presented reflect real life experience with DAL in treating PJI with a homogeneous dosing scheme. Safety, tolerability and efficacy were excellent. In the absence of a clinical trial, this case series presents the results of a cohort patients with complex co-morbidities and difficult to treat microorganisms. In our view, DAL therapy allowed clinicians to deal with PJI cases in which no other options aside from daptomycin and vancomycin were available, providing patients with a safe, comfortable and effective outpatient treatment resulting in excellent outcome.

To our knowledge, this is the largest single center report on the use of DAL for PJI. Currently, no standard recommendation regarding dosage and duration of treatment exists. Our experience shows that DAL administration for treating Gram-positive PJI allows earlier discharge, reducing hospital stay, and seems to be safe, effective and cost saving. Besides, our study suggests that DAL administration every two weeks (the LDDB regimen) seems to be an effective dosing scheme. Our preliminary results and the true role of DAL in the treatment of PJI should ideally be confirmed by future studies.

ACKNOWLEDGEMENTS

Dr. Buzón Martín is grateful to Dr. Javier Cobo Reinoso MD, Dra. Noemi Gómez Manero and Dr. Pedro Delgado López for their review of the manuscript and recommendations.

FUNDING

None to declare

CONFLICT OF INTEREST

LBM has received lecture fees from Angelini Pharmaceuticals. No other conflict of interest is reported.

REFERENCES

1. Williams SN, Wolford ML, Bercovitz A. Hospitalization for Total Knee Replacement Among Inpatients Aged 45 and Over: United States, 2000–2010. NCHS Data Brief 2015 (210): 1. PMID: 26375255
2. Kurtz SM, Ong KL, Lau E, Bozic KJ, Berry D, Parvizi J. Prosthetic joint infection risk after TKA in the Medicare population. Clin Orthop Relat Res. 2010; 468(1): 52. PMID:19669386
3. Bassetti M, Peghin M, Carnelutti A, Righi E. The role of dalbavancin in skin and soft tissue infections. Curr Opin Infect Dis.2018; 31(2): 141. PMID:29298166
4. Tobudic S, Forstner C, Burgmann H, Lagler H, Ramharter M, Steininger C, et al. Dalbavancin as primary and sequential treatment for Gram-positive infective endocarditis: 2-Year Experience at the General Hospital of Vienna. Clin Infect Dis. 2018; 67(5):795–798. PMID:29659732
5. Dunne MW, Puttagunta S, Sprenger CR, Rubino C, Van Wart S, Baldassarre J. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. Antimicrob Agents Chemother. 2015; 59(4): 1849. PMID:25561338
6. Nair T, Fitzgerald J, Ly B, Wallace MR. Dalbavancin as a cost effective antibiotic. Infect Dis (Lond). 2018; 50(1): 75. PMID: 28805474
7. Gehrke T, Parvizi J. Proceedings of the International Consensus Meeting on Periprosthetic Joint Infection. J Arthroplasty. 1 de febrero de 2014;29(2):4. PMID: 24151261
8. Canton R, Diez-Aguilar M, Morosini ML. [Dalbavancin breakpoints and recommendations for in vitro study of its activity]. Enferm Infecc Microbiol Clin. 2017; 35 Suppl 1: 15. PMID: 28129815
9. Bouza E, Valerio M, Soriano A, Morata L, Carus EG, Rodriguez-Gonzalez C, et al. Dalbavancin in the treatment of different Gram-positive infections: a real-life experience. Int J Antimicrob Agents. 2018; 51(4): 571. PMID: 29180276
10. Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerman W, Steckelberg JM, et al. Executive summary: diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2013; 56(1): 1. PMID: 23230301
11. Biedenbach DJ, Bell JM, Sader HS, Turnidge JD, Jones RN. Activities of dalbavancin against a worldwide collection of 81,673 Gram-positive bacterial isolates. Antimicrob Agents Chemother. 2009; 53(3): 1260. PMID: 19124664
12. Cercenado E. [Antimicrobial spectrum of dalbavancin.
Dalbavancin for treating prosthetic joint infections caused by Gram-positive bacteria: A proposal for a low dose strategy. A retrospective cohort study
L. Buzón Martín, et al.
Rev Esp Quimioter 2019;32(6): 532-538

Mechanism of action and in vitro activity against Gram-positive microorganisms]. Enferm Infecc Microbiol. 2017; Clin 35 Suppl 1: 9. PMID: 28129822

13. Knaff D, Tobudic S, Cheng SC, Bellamy DR, Thalhammer F. Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE). Eur J Clin Microbiol Infect Dis. 2017; 36(4): 677. PMID: 27896496

14. Rappo U, Puttagunta S, Shevchenko V, Shevchenko O, Jandourek A, Gonzalez PL, et al. Dalbavancin for the treatment of osteomyelitis in adult patients: A randomized clinical trial of efficacy and safety. Open Forum Infect Dis 6(1) 2019, ofy331

15. El Haj C, Ribera A, Lloberas N, Tubau F, Ariza J, Murillo O. Drawbacks of the use of cotrimoxazole in foreign-body infections. Enferm Infecc Microbiol Clin. 2018; 36(6): 362. PMID: 28818482

16. Karkow DC, Kauer JF, Ernst EJ. Incidence of Serotonin Syndrome With Combined Use of Linezolid and Serotonin Reuptake Inhibitors Compared With Linezolid Monotherapy. J Clin Psychopharmacol. 2017; 37(5): 518. PMID: 28796019

17. Gonzalez-Del Castillo J, Candel FJ, Manzano-Lorenzo R, Arias L, Garcia-Lamberechts EJ, Martin-Sanchez FJ. Predictive score of haematological toxicity in patients treated with linezolid. Eur J Clin Microbiol Infect Dis. 2017; 36(8): 1511. PMID: 28343274

18. Jones BM, Keedy C, Wynn M. Successful Treatment of Enterococcus faecalis Bacteremia with Dalbavancin as an Outpatient in an Intravenous Drug User. Int J Infect Dis. 2018; 76: 4-5. PMID: 30053580

19. Pfaller MA, Flamm RK, Castanheira M, Sader HS, Mendes RE. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016). Int J Antimicrob Agents. 2018; 51(4): 608. PMID: 29277526

20. Neudorfer K, Schmidt-Malan SM, Patel R. Dalbavancin is active in vitro against biofilms formed by dalbavancin-susceptible enterococci. Diagn Microbiol Infect Dis. 2018; 90(1): 58. PMID: 29195766